2017 asco recap: the latest in colorectal cancer research #crcwebinar
TRANSCRIPT
![Page 1: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/1.jpg)
2017 ASCO RECAP: The Latest in
Colorectal Cancer Research
Our webinar will begin shortly.
WELCOME!
![Page 2: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/2.jpg)
• Speaker: Dustin Deming, MD
• Archived Webinars: FightCRC.org/webinars
• AFTER THE WEBINAR: Expect an email with links to the
material & a survey. If you fill it out, we’ll send you an “I
booty” bracelet
• Ask a question in the panel on the RIGHT SIDE of your
screen
• Follow along via Twitter – use the hashtag #CRCWebinar
Today’s Webinar:
![Page 3: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/3.jpg)
Resources:
![Page 4: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/4.jpg)
Disclaimer
:
The information and services provided by Fight Colorectal
Cancer are for general informational purposes only. The
information and services are not intended to be substitutes
for professional medical advice, diagnoses or treatment.
If you are ill, or suspect that you are ill, see a doctor
immediately. In an emergency, call 911 or go to the nearest
emergency room.
Fight Colorectal Cancer never recommends or endorses any
specific physicians, products or treatments for any condition.
![Page 5: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/5.jpg)
Speaker:
Dustin Deming, MD, is a gastrointestinal
oncologist and colorectal cancer laboratory
researcher at the University of Wisconsin Carbone
Cancer Center.
He has a subspecialty focus in the treatment of
colon, rectal and anal cancers. At the age of 31, he
was diagnosed with stage III rectal cancer, the very
disease he has dedicated to treating and advancing
therapies for.
As both a practitioner, researcher AND a patient, he
knows first-hand what the cancer journey is like; he
aims his research to fundamentally change the way
in which we treat gastrointestinal cancers to amore
personalized approach.
![Page 6: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/6.jpg)
ASCO Update 2017:Colorectal Cancer
Dustin Deming, MD
McArdle Laboratory for Cancer Research
Carbone Cancer Center
University of Wisconsin
6/23/2017
![Page 7: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/7.jpg)
Outline
• Metastatic Cancer: Advances in Immunotherapy
• Metastatic Cancer: Advances in Precision Medicine
• Adjuvant Chemotherapy: 3 vs 6 months
• Survivorship Care
![Page 8: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/8.jpg)
Metastatic Cancer: Advances in Immunotherapy
• Nivolumab and Ipilimumab for MSI-H CRC
• CEA-TCB Bispecific Antibody
• Versican Proteolysis as a New Immune Biomarker
![Page 9: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/9.jpg)
Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
Presented by: Thierry Andre, MD
![Page 10: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/10.jpg)
Nivolumab and Ipilimumab for MMR deficient cancers
![Page 11: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/11.jpg)
Nivolumab and Ipilimumab for MMR deficient cancers
![Page 12: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/12.jpg)
Nivolumab and Ipilimumab for MMR deficient cancers
![Page 13: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/13.jpg)
Nivolumab and Ipilimumab for MMR deficient cancers
![Page 14: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/14.jpg)
CEA-TCB Antibody
![Page 15: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/15.jpg)
Safety profile of CEA-TCB was manageable as monotherapy and <br />in combination with atezolizumab
Presented By Josep Tabernero at 2017 ASCO Annual Meeting
![Page 16: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/16.jpg)
CEA-TCB at doses of ≥ 60 mga demonstrated clinical activity in mCRC as monotherapy and in combination with atezolizumab
Presented By Josep Tabernero at 2017 ASCO Annual Meeting
![Page 17: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/17.jpg)
CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated enhanced clinical activity vs monotherapy in mCRC
Presented By Josep Tabernero at 2017 ASCO Annual Meeting
![Page 18: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/18.jpg)
CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated promising clinical activity in 3L+ patients with MSS mCRC
Presented By Josep Tabernero at 2017 ASCO Annual Meeting
![Page 19: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/19.jpg)
Versican Proteolysis
• A new biomarker for immune infiltration in colorectal cancers
![Page 20: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/20.jpg)
Interaction Between Cancer Genomics and the Tumor Microenvironment
Dr. Fotis Asimakopoulos
![Page 21: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/21.jpg)
VCAN Proteolysis Correlates with CD8+ T-Cell Infiltration
![Page 22: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/22.jpg)
Metastatic Cancer: Advances in Precision Medicine• Cetuximab, Vemurafenib and Irinotecan for BRAF
mutant cancers
![Page 23: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/23.jpg)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 24: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/24.jpg)
Introduction
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 25: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/25.jpg)
Study Design
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 26: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/26.jpg)
Grade 3/4 Adverse Events
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 27: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/27.jpg)
Primary Endpoint: Progression-free survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 28: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/28.jpg)
Response Rate
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 29: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/29.jpg)
Subgroup Analyses
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 30: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/30.jpg)
Secondary Endpoint: Overall Survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting
![Page 31: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/31.jpg)
Adjuvant Chemotherapy for Stage III Colon Cancer:
3 vs 6 months duration
![Page 32: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/32.jpg)
Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: <br />The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 33: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/33.jpg)
Study Schema
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 34: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/34.jpg)
IDEA Trials Summary
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 35: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/35.jpg)
Adverse Events
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 36: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/36.jpg)
Primary DFS Analysis (mITT)
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 37: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/37.jpg)
Primary DFS Analysis (mITT), cont.
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 38: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/38.jpg)
DFS Comparison by Risk Group and Regimen, cont.
Presented By Qian Shi at 2017 ASCO Annual Meeting
![Page 39: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/39.jpg)
![Page 40: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/40.jpg)
Recommendations Going Forward
Ways Oncologists are Thinking About this Data
• 6 months of adjuvant chemotherapy for everyone
• 3 months for low risk and 6 months for high risk
• Give oxaliplatin for first 3 months only, and finish with infusional 5FU for total of 6 months
• Maybe CAPEOX is better than FOLFOX
Dusty’s Opinion
• Risk/benefit ratio approach
![Page 41: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/41.jpg)
Survivorship Care
• Tree Nuts
• Vitamin D
• PET/CT scans
![Page 42: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/42.jpg)
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)
![Page 43: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/43.jpg)
CALGB 89803
![Page 44: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/44.jpg)
Slide 13
![Page 45: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/45.jpg)
Results
![Page 46: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/46.jpg)
Some preclinical rationale
![Page 47: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/47.jpg)
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)
![Page 48: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/48.jpg)
Vitamin D by Tertile with Outcome
![Page 49: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/49.jpg)
Secondary analyses of 89803
![Page 50: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/50.jpg)
What do I do or at least try to do?
• Aspirin – 81-325mg per day
• Exercise – Half hour of moderate exercise more days than not
• Multi-vitamin
• Low glycemic index diet
• Coffee
• Tree nuts or tree nut products
![Page 51: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/51.jpg)
Question & Answer:
SNAP A #STRONGARMSELFIEBayer HealthCare will donate $1 for every photo posted (up to $25,000).
Flex a “strong arm” & post it to Twitter or Instagram! (Use the hashtag!)
![Page 52: 2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinar](https://reader031.vdocuments.net/reader031/viewer/2022022415/5a658cef7f8b9a931a8b6b77/html5/thumbnails/52.jpg)
Contact Us!